arrow
A

Anna Saborowski

Hannover Medical School
H指数:25
被引数:4,612

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world data from patients treated with chemotherapy for biliary tract cancer: insights from a prognostic model. ☆

真实世界数据:化疗治疗胆道癌患者的预后模型分析<sup><em>☆</em></sup>

2026-09-220
OA
2026-09-200
PRE
Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study

胆道癌患者接受化疗免疫疗法后的预后分层:一项回顾性多中心真实世界研究

Cancer
IF5.1
2026-09-160
PRE
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

胆道癌患者接受化疗免疫疗法治疗后不良事件预测作用的全球人群研究

Cancers
IF4.4
2026-09-100
OA
Futibatinib after Non-Covalent FGFR Inhibitors in FGFR2-Rearranged Intrahepatic Cholangiocarcinoma: Clinical Activity and Resistance Patterns

富替比替尼在FGFR2重排型肝内胆管癌中作为非共价FGFR抑制剂后的临床活性及耐药模式

2026-09-090
PRE
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting

根据TOPAZ-1研究入组标准评估顺铂、吉西他滨和度伐利尤单抗的疗效:一项真实世界环境下的全球性大规模分析

2026-08-160
PRE
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab

探索系统性治疗后的手术治疗在局部晚期胆道癌中的作用:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的大型回顾性跨国真实世界队列的结局

2026-08-150
PRE
Machine learning for population-level risk prediction of future cholangiocarcinoma

机器学习用于未来胆管癌的群体水平风险预测

2026-08-120
OA
Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: the IKF-t006/IMMUNIB translational phase-2 study

纳武利尤单抗联合仑伐替尼治疗不可切除性肝细胞癌:IKF-t006/IMMUNIB转化性Ⅱ期研究

2026-06-030
OAAI
A Retrospective Multicenter Study Identifies a Similar Overall Survival of Patients After Liver Transplantation With Incidental Cholangiocarcinoma Compared to Hepatocellular Carcinoma

一项回顾性多中心研究确定了与肝细胞癌相比,意外发现的胆管癌肝移植患者具有相似的总生存期

2026-05-190
OAAI
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab

接受顺铂、吉西他滨和度鲁特韦治疗的胆道癌患者中,转移部位对预后的影响

2026-02-270
PRE
Cholangiocarcinoma 2026: status quo, unmet needs and priorities

胆管癌2026: 现状,未满足的需求和优先事项

2025-12-100
OAAI
Clinical practice and implications of biomarker testing in biliary tract cancer: an observational study☆

胆道癌中生物标志物检测的临床实践与意义:一项观察性研究☆

2025-11-040
OAAI
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE